leflunomide
Term · Oncology and biomedicine · MLC-T-ONC-004768
An anticancer drug that works by inhibiting a cancer cell growth factor. Also called SU101.
A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties. As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes. This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation.
| Identifier | MLC-T-ONC-004768 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | SU101 |
| References | NCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-004768",
"term": "leflunomide",
"field": "Oncology and biomedicine",
"definitions": [
"An anticancer drug that works by inhibiting a cancer cell growth factor. Also called SU101.",
"A derivative of isoxazole used for its immunosuppressive and anti-inflammatory properties. As a prodrug, leflunomide is converted to an active metabolite, A77 1726, which blocks dihydroorotate dehydrogenase, a key enzyme of de novo pyrimidine synthesis, thereby preventing the expansion of activated T lymphocytes. This agent also inhibits various protein tyrosine kinases, such as protein kinase C (PKC), thereby inhibiting cell proliferation."
],
"synonyms": [
"SU101"
],
"references": [
"NCI Dictionary of Cancer Terms",
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/leflunomide/"
}
Record 9,994 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.